Meanwhile, perioperative anti-tumor drugs, especially anthracycline and taxane-based chemotherapy regimens, have been established to treat HER2− early-stage breast cancer at high risk of recurrence [17–23]. This evidence concerns the gene ERBB2 and breast carcinoma.